Downhill running-induced muscle damage. Myalgia
Conditions
Interventions
Intervention 1: Each participant will receive dextrose (0.3 g/kg body weight/day) for five consecutive days.
After the supplementation period, all subjects will participate in one bout downhill runni
Placebo
Treatment - Drugs
Each participant will receive dextrose (0.3 g/kg body weight/day) for five consecutive days.
After the supplementation period, all subjects will participate in one bout downhill running protocol on
Each participant will receive creatine monohydrate (0.3 g/kg body weight/day) for five consecutive days (Loading Phase).
After the supplementation period, all subjects will participate in one bout d
Sponsors
Graduate office in University of Tabriz
Eligibility
Sex/Gender
Male
Age
22 Years to 28 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria :Healthy males; mountain climbers; aged 22-28 years; BMI 18-22 Kg/m2; High jump more than 45 cm; aerobic power more than 50 ml/kg/min; at least 3 years sport history; without any anti-inflammatory and medical drugs during 6 months prior to the study. Exclusion criteria: chronic diseases; injuries; uncontrolled intake of oxidative supplements; uncontrolled intake of anti-inflammatory drugs or stimulants such as caffeine>100 mg/day (during the period).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-reacive protein. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: immunoturbidometric assay.;IL-6. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: ELISA methods with commercial kits.;Total Serum Cereatine kinase (CK). Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: Photometric methods with commercial kits (Pars-Azmoon).;Peripheral blood leukocyte count. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: It will determine by automatic analyzer.;Perceived soreness. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: Talag Scale.;Muscle circumstance. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: It will determine by flexible tap.;Lower limb flexibility. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: Sit and reach test (wells).;Lower limb maximal isometric strength. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: Dynamometric measurement.;Lower limb power. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: Sargent vertical jump test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Peripheral blood lactate. Timepoint: Before and immediately after downhill running protocol. Method of measurement: It will determine by with commercial Randox kits.;Serum Total antioxidant capacity (TAC). Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: by Frap Method.;Serum Malondialdehyde. Timepoint: Before and after 5-day creatine supplementation, 30 min before and immediately and 24 hours after downhill running protocol. Method of measurement: by thiobarbituric acid reactive substance (TBARS) and spectrophotometer. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed